Biofrontera AG Share Price OTC Markets
Equities
BFRA
US09075G1058
Pharmaceuticals
Sales 2021 | 28.79M 31.02M 2.59B | Sales 2022 | 25.74M 27.73M 2.32B | Capitalization | 97.31M 105M 8.75B |
---|---|---|---|---|---|
Net income 2021 | 38M 40.95M 3.42B | Net income 2022 | -44M -47.41M -3.96B | EV / Sales 2021 | 2.79 x |
Net cash position 2021 | 3.61M 3.89M 325M | Net cash position 2022 | 4.88M 5.25M 439M | EV / Sales 2022 | 3.59 x |
P/E ratio 2021 |
2.18
x | P/E ratio 2022 |
-1.98
x | Employees | 92 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 32.4% |
Latest transcript on Biofrontera AG
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | 55 | 12/22/12 | |
Anke zur Muehlen
IRO | Public Communications Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 14/21/14 | |
Director/Board Member | - | 14/21/14 | |
Heikki Lanckriet
BRD | Director/Board Member | 46 | 14/21/14 |
1st Jan change | Capi. | |
---|---|---|
+32.36% | 695B | |
+26.51% | 568B | |
-4.40% | 361B | |
+19.46% | 330B | |
+3.50% | 283B | |
+16.34% | 239B | |
+6.68% | 204B | |
-9.08% | 198B | |
+8.62% | 168B |